This opportunity is no longer accepting applications.
grant RFA-AG-25-004

Safety and Early Efficacy Studies of Psychedelic-Assisted Therapy for Chronic Pain in Older Adults (UG3/UH3 Clinical Trial Required)

This grant opportunity aims to support a multi-center consortium to form a clinical trials network focused on older adults with chronic pain conditions. The funding mechanism is phased into UG3 and UH3 stages. The UG3 phase, lasting up to 2 years, involves initial studies in healthy older adults to assess the safety and effects of psychedelic agents, which include substances like psilocybin, L…

The purpose of this funding opportunity is to support a multi-center consortium that will function as a clinical trials network to collect safety and early efficacy data in defined groups of older adults with specific chronic pain conditions. This funding opportunity will use a UG3/UH3 phased in…

Funding Source

Agency: National Institutes of Health
Program: SBIR

Dates

Application Window Closes: October 10, 2024
Opportunity Released: April 24, 2024
Open for Submission: April 24, 2024
Submission Deadline: October 10, 2024

Documents

Secure Grant Funding 10x Faster

Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.

Already have an account? Sign In

Trusted by 500+ Happy Customers

Get opportunities sent to your inbox

The latest grant news and insights from our experts.

Save this opportunity and explore more

Share Opportunity

Share this opportunity with others.
Anyone with this link can view the opportunity details.